Bioprocessing Cell Lines

Graphic of recombinant platform featuring CHOZN® GS / CHO cell line and UCOE® expression technology

A cell line that maintains favorable growth and productivity characteristics is vital for biopharmaceutical manufacturing processes, whether you are producing monoclonal antibodies, recombinant proteins, or viral vectors for gene therapies. Our ready-to-use cell line systems can accelerate your upstream development by greatly reducing the time, cost, and risk of developing new cell lines. Our cell lines are rationally engineered and designed for compliant biomanufacturing.

Key features include:

  • Fully traceable cell lines with comprehensive documentation
  • cGMP banked and characterized
  • Paired, optimized, and chemically defined media and feeds
  • Comprehensive user protocols for efficient cell line development and seamless scale-up, supported by technical consultation

Related Product Resources


CHOZN® Platform for Production of Biologics and Recombinant Proteins

Our CHOZN® platform is a Chinese Hamster Ovary (CHO) mammalian cell expression system that allows for faster, simpler selection and scale-up of high-producing clones for production of biologics and therapeutic recombinant proteins. It includes:

  • High-performing CHO cell lines
  • Paired media and feeds
  • Optimized expression vectors
  • Robust protocols

Three CHOZN® cell lines are available:

  • CHOZN® GS -/- cell line, enabling rapid cell line development without the need for amplification by MTX metabolic selection agent
  • CHOZN® DHFR -/- cell line, enabling rapid cell line development by amplification via MTX metabolic selection agent
  • CHOZN® CHO K1 cell line, enabling rapid cell line development with the metabolic selection agent of choice

Powered by CompoZr® Zinc Finger Nuclease (ZFN) technology, the well-known and widely adopted CHOZN® GS-/- cell line can help shorten cell line development time lines by up to eight weeks while ensuring excellent stability, with >75% of clones maintaining >70% titer of 60 generations.

Optimized expression vectors for the CHOZN® GS -/- cell line include:

  • pCGS3.2 standard CHOZN® GS expression vector
  • UCOE® GS expression vector using the chromatin opening UCOE® expression technology
Graphic of recombinant platform featuring CHOZN® GS -/- CHO cell line and UCOE® expression technology

VirusExpress™ Lentiviral Production Platform

Our VirusExpress™ platform offers a transfection-based solution for lentiviral (LV) production challenges, featuring a suspension adapted cell line, chemically defined medium, and process with proven performance at clinically relevant scale. The platform can dramatically reduce time in process development and scale-up, either within your own facilities or using our contract manufacturing capabilities to speed your therapy to patients. Attributes include:

  • cGMP banked and characterized cells
  • Chemically defined medium
  • Proven performance for cell growth, plasmid transfection, and lentiviral production in bioreactors at scale
  • License available for clinical and commercial use

VirusExpress™ 293T Lentiviral Production Cells are optimized for production of lentiviral vectors for gene therapy applications. Comprehensive user protocols guide you from seed train through at-scale transfection and virus production, allowing seamless scale-up. Robust quality documentation enables regulatory filings and commercialization of your gene-modified cell therapy.